In terms of the kidney complication, the patients who are severely insulin resistant are at high risk to develop DKD.70 The potential of SHIP2 inhibitors to act as insulin sensitizers highlights their potential to provide new leads for personalized medications for this subgroup of patients. The gene discussed is INPPL1; the disease is diabetic kidney disease.